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Abstract
Background: A diverse B-cell repertoire is essential for recognition and response to infectious and vaccine
antigens. High-throughput sequencing of B-cell receptor (BCR) genes can now be used to study the B-cell
repertoire at great depth and may shed more light on B-cell responses than conventional immunological methods.
Here, we use high-throughput BCR sequencing to provide novel insight into B-cell dynamics following a primary
course of hepatitis B vaccination.
Methods: Nine vaccine-naïve participants were administered three doses of hepatitis B vaccine (months 0, 1, and 2
or 7). High-throughput Illumina sequencing of the total BCR repertoire was combined with targeted sequencing of
sorted vaccine antigen-enriched B cells to analyze the longitudinal response of both the total and vaccine-specific
repertoire after each vaccine. ELISpot was used to determine vaccine-specific cell numbers following each vaccine.
Results: Deconvoluting the vaccine-specific from total BCR repertoire showed that vaccine-specific sequence
clusters comprised <0.1 % of total sequence clusters, and had certain stereotypic features. The vaccine-specific BCR
sequence clusters were expanded after each of the three vaccine doses, despite no vaccine-specific B cells being
detected by ELISpot after the first vaccine dose. These vaccine-specific BCR clusters detected after the first vaccine
dose had distinct properties compared to those detected after subsequent doses; they were more mutated, present
at low frequency even prior to vaccination, and appeared to be derived from more mature B cells.
Conclusions: These results demonstrate the high-sensitivity of our vaccine-specific BCR analysis approach and
suggest an alternative view of the B-cell response to novel antigens. In the response to the first vaccine dose, many
vaccine-specific BCR clusters appeared to largely derive from previously activated cross-reactive B cells that have
low affinity for the vaccine antigen, and subsequent doses were required to yield higher affinity B cells.
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Background
B-cell repertoire diversity is a key feature of the humoral
immune system, creating the potential for recognition of
the wide variety of antigens likely to be encountered
during an individual’s lifetime. The great diversity of this
system, capable of generating up to 1011 unique B-cell
receptor (BCR) variants [1], precludes analysis by con-
ventional immunological techniques. Advances in next-
generation sequencing technology now allow compre-
hensive characterization of B-cell samples at the level of
their BCR DNA sequence. This technology is starting to
yield insight into the dynamics of the B-cell response fol-
lowing antigen stimulation [2–7] and has great potential
for increasing our understanding of humoral immunity
and in vaccine development [8].
Laserson et al. showed that certain clones within the
global B-cell repertoire undergo rapid expansions and
contractions in response to vaccination [3]. However,
these expansion dynamics were qualitatively different in
different individuals and were not related to vaccine type
* Correspondence: jacob.galson@paediatrics.ox.ac.uk
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford and
the NIHR Oxford Biomedical Research Center, Oxford OX3 7LE, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Galson et al. Genome Medicine  (2016) 8:68 
DOI 10.1186/s13073-016-0322-z
or efficacy. We and others have also shown that the total
repertoire undergoes stereotypic changes following vac-
cination—the repertoire has an increase in mutation and
a decrease in diversity 7 days following vaccination, con-
sistent with an increase in the number of mutated
plasma cells (PCs) released into the peripheral blood at
this time [2, 5, 6]. A small number of similar clones also
appear to be produced in different individuals (the so-
called public repertoire) after they receive the same anti-
gen [2, 4, 7, 9]. Relating changes in the global repertoire
to vaccine response is challenging as these repertoire
dynamics may be confused with concurrent subclinical
responses to irrelevant antigens [10]. Focusing on the
public repertoire can overcome this to an extent [7], but
the public repertoire is also enriched for clones specific
to antigens that are commonly encountered by the popu-
lation (e.g., tetanus toxoid, influenza) [10] and it is not
clear to what extent the functional properties of the public
antigen-specific repertoire and the private antigen-specific
repertoire are different.
We designed the present study to overcome the diffi-
culties of discerning the vaccine-specific from total rep-
ertoire and to give clearer insight into B-cell dynamics
following vaccination. Hepatitis B (HepB) vaccine was
used as the stimulus; this is a monovalent vaccine con-
sisting of HepB surface antigen (HBsAg) and alum adju-
vant. We hypothesized that the HepB vaccine response
might be simpler to interpret than the response to a
multivalent vaccine. In the United Kingdom, HepB vac-
cine is not given routinely so we were able to recruit
HepB-naïve individuals and study the primary response.
Primary HepB vaccination consists of three separate
doses so we could also study how the response changed
between the doses (Additional file 1: Figure S1). To this
extent, we sequenced IgG transcripts from 500,000 total B
cells on the day of and 7 days following each vaccine to
gain insight into total repertoire dynamics. Cell sorting
was also performed to enrich for vaccine-specific cells and
sequencing these enabled generation of a vaccine-
enriched sequence database. This database was combined
with a HepB vaccine-enriched database generated in the
same way from a previous HepB vaccine study [2], enab-
ling us to distinguish the sequence clusters within the total
repertoire that were vaccine-specific. Studying the
vaccine-specific cluster dynamics gave a clearer signal of
vaccine response and indicated a surprising role for previ-
ously generated memory B cells in the response to the first
dose of vaccine.
Methods
Participants and vaccinations
Nine healthy subjects (aged 20–38 years) with no prior
history of HepB vaccination or infection were recruited
with informed consent in accordance with the Declaration
of Helsinki and under approval from the Northampton
Research Ethics Committee (13/EM/0036). As this was an
observational study and given good response rates to this
vaccine, nine participants was estimated to be a large
enough sample to describe vaccine responses in this sys-
tem. Participants were given a three-dose primary regime
of monovalent HepB vaccine containing 10 μg HBsAg
adsorbed on amorphous aluminum hydroxyphosphate
sulfate (HBvaxPRO®, Sanofi Pasteur). Five participants
were given a standard schedule (0, 1, and 7 months) and
four participants were given an accelerated schedule (0, 1,
and 2 months). Blood was taken immediately before vac-
cination, 7 days following each vaccination, and 1 month
following the final vaccine (Additional file 1: Figure S1).
Blood was transferred to a heparinized tube for processing
within 4 h of collection.
Anti-HBsAg antibody testing
Blood serum was isolated by centrifugation and tested
for anti-HBsAg IgG antibody concentration by ELISA at
the microbiology laboratory, John Radcliffe Hospital,
Oxford.
ELISpot
ELISpot was used to determine the number of HBsAg-
specific memory and PCs using a previously described
protocol [2]. Briefly, peripheral blood mononuclear cells
(PBMCs) were first isolated from whole blood by
density-gradient centrifugation. Multiscreen-IP 96-well
ELISpot plates (Millipore) were coated with 2.5 μl/ml
HBsAg (GSK). For detection of PCs, 200,000 PBMCs
were added directly into each well of the plate, and for
detection of memory cells, PBMCs were first incubated
for 6 days in activation medium before addition to the
plate. For each sample, the mean spot count was taken
from six wells conducted in parallel.
Cell sorting
B cells were magnetically enriched from PBMCs using
CD19 microbeads (Miltenyi Biotec). For each sample,
500,000 B cells were isolated for sequencing the total
repertoire and the remaining labeled with live/dead-
aqua, CD19-FiTC, CD20-APCH7, CD27-PECy7, CD38-
PE, HLA-DR-PerCPCy5, and HBsAg-APC. The specifi-
city of HBsAg-APC staining was previously shown to be
at least 50 % by use of a competition assay with unconju-
gated HBsAg [2]. On visits 2–7, viable, CD19+, CD20+,
HBsAg+ B cells were isolated using a MoFlo cell sorter
(Beckman Coulter) and on visits 2, 4 and 6, viable, CD19+,
CD20low/−, CD27+, CD38+, HLA-DR+ PCs were isolated.
Sorted cells were frozen at −80 °C in RLT buffer (Qiagen)
until use.
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Repertoire sequencing
RNA was extracted from sorted cells using the RNeasy
Mini Kit (Qiagen) and reverse transcription performed
using SuperScript III (Invitrogen) and random hexamer
primers (42 °C for 60 min, 95 °C for 10 min). PCR was
conducted using the Multiplex PCR kit (Qiagen) with
VH-family specific forward primers and IgG-specific re-
verse primers [11] (94 °C for 15 min, 30 cycles of 94 °C
for 30 s, 58 °C for 90 s and 72 °C for 30 s, and 72 °C for
10 min). Amplicons were gel-extracted and purified
prior to library preparation. Samples were multiplexed
and sequenced across three 2 × 300 bp MiSeq (Illumina)
runs.
Sequence processing
Paired-end reads were joined using fastq-join (ea-utils)
with default settings and filtered for minimum Phred
quality of 30 over at least 75 % of bases. IMGT/HighV-
Quest [12] was used for sequence annotation and unpro-
ductive sequences were removed. For total B-cell reper-
toire samples, subsampling to 75,000 sequences per
sample was conducted and sequences were clustered
into clonal lineages using a previously described algo-
rithm [10]. To be considered part of the same cluster,
sequences were required to have identical V and J genes
and identical complementarity determining region
(CDR) 3 length and were allowed 1 mismatch for every
15 nucleotides in the CDR3 sequence. The sequencing/
PCR error rate of the methodology was previously esti-
mated to be 0.0079 [10], so there will be some erroneous
sequences in the dataset. The clustering approach used
will group together reads arising from error as well as
clonally related B cells. This means that, for analysis at
the repertoire level, cluster size is used as a proxy for
error-corrected B-cell abundance. For analysis of lineage
trees of sequences within the clusters, we chose not to
attempt removal of erroneous sequences due to difficul-
ties in distinguishing error from somatic hypermutation,
so it should be noted that these erroneous sequences
will add some systematic noise to the analysis.
Annotating clusters for putative antigenic specificity
Sequence data from sorted PC+ and HBsAg+ samples
were compared with the total repertoire data to annotate
clusters in the total repertoire for putative vaccine speci-
ficity. To match a sequence from the sorted data with a
cluster in the total repertoire, it was required to utilize
the same V and J gene segment and have a highly similar
CDR3 amino acid sequence to the dominant sequence
in the cluster (≥96 % identity). This matching approach
means that sequences arising from sequencing/PCR
error in the PC+ and HBsAg+ datasets will end up anno-
tating the same cluster so do not need to be corrected
for prior to matching. Sequences were also only matched
back to participants from whom they were not obtained
in order to reduce the effect of non-specific matching.
PC+ and HBsAg+ samples from a previous study of
HepB booster vaccination were also compared with the
total repertoire data in the same way [2]. In addition, se-
quences from previously described HBsAg-specific clus-
ters from the literature were compared with the total
repertoire in the same way.
Statistical analysis and graphing
Statistical analysis was performed using R [13], with
ggplot2 [14] for graphing. Principal component analysis
was performed using the prcomp function in the “stats”
package [13]. Rarefaction analysis was conducted using
the “iNEXT” package [15] using a q value of 0.
Lineage trees were constructed from sequence clusters
using the “alakazam” package [16]. Lineages were only
generated for clusters with at least 50 or 25 sequences
depending on the analysis, and subsampling was per-
formed if there were more than this number. The diversity
of lineages was calculated using the Shannon entropy
index with the “vegan” package [17], treating sets of
unique sequences (nucleotide level) of the same length as
independent species.
To determine antigen-driven selection pressures, the
BASELINe framework was used with the focused test to
analyze the distribution of mutations in the CDR and
framework regions [18].
Results
Vaccine-specific cells are detected after vaccines 2 and 3
but not after vaccine 1
ELISpot was used to determine the number of HBsAg-
specific IgG PCs and memory cells in the peripheral
blood at each visit (Fig. 1). The number of PCs detected
7 days following the first vaccine (visit 2) was negligible
and PCs were only produced in detectable numbers
7 days following the second and third doses (visits 4 and
6, respectively). Despite considerable inter-individual vari-
ation in the response, with some participants having a
greater PC peak at visit 4 and some at visit 6 (Additional
file 1: Figure S2), the mean magnitude of the response was
similar after each of these vaccines (at visit 4, mean 13
antibody-secreting cells (ASCs)/106 PBMCs, range 0–58;
at visit 6, mean 14 ASCs/106 PBMCs, range 0–44). The
number of memory cells detected increased steadily
throughout the course of the study, reaching the greatest
number at the final visit (Fig. 1). All participants had an
anti-HBsAg antibody concentration greater than 10 mIU/
ml at the end of the study. The response after the third
vaccine dose was slightly greater in the group given the 0,
1, and 7 month schedule, although the study was not
powered to detect such differences.
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Sequencing the total B-cell repertoire
Total IgG repertoire data were successfully obtained
from all samples except one, where a blood sample could
not be obtained. On average, 308,100 (range 240,000–
355,900) raw illumina sequencing reads were obtained
for each sample, of which 111,200 (range 75,870–
136,100) remained after all filtering steps (Additional
file 1: Table S1). Samples were subsampled to give
75,000 sequences for each and clustering performed.
Clustering is used to group together clonally related se-
quences from each participant as well as for error cor-
rection by grouping together sequences which have
arisen due to PCR or sequencing error. The threshold
for clustering was set based on determining the CDR3
sequence nearest neighbor distribution for all sequences
in the dataset (Additional file 1: Figure S3a). This distri-
bution has two modes: the first represents sequences
with clonal relatives (or erroneous sequences) and the
second represents singletons. A clustering threshold of
1 nucleotide per 15 nucleotides was used to separate
these two modes (Additional file 1: Figure S3a, b). On
average, 12,212 (range 4081–19,304) clusters were gen-
erated from each sample. Rarefaction analysis indicated
that our sampling of total clusters in the sample was
tending towards saturation for most samples (Additional
file 1: Figure S3c).
We previously showed an increase in cluster expan-
sions, mutation, and sequence convergence between par-
ticipants and a decrease in CDR3 amino acid
(AA) sequence length following administration of HepB
booster vaccine [2]; we thus determined the same prop-
erties in the current dataset. We did observe expansion
of some clusters at each of the day 7 visits following
each vaccine (Fig. 2a); however, this was only significant
following the third dose of vaccine and there were also
striking cluster expansions in two of the participants at
baseline (Additional file 1: Figure S4). Changes in mutation
and CDR3 length were not significant in this dataset
(Fig. 2b, c). The size of the public repertoire did increase
following the second and third vaccinations but the in-
crease was only significant following the third vaccination
(Fig. 2d).
Enriching for the vaccine-specific repertoire
From each participant, we were able to isolate and se-
quence, on average, 26,720 HBsAg+ B cells in total across
visits 2–7 and 2748 PCs on the day 7 visits (Additional file
1: Table S2). These data were combined with sequence
data from 85,000 HBsAg+ cells and 3444 PCs obtained
after HepB booster vaccine from our previous study [2] to
create a large vaccine-enriched sequence database. Using
these vaccine-enriched sequences to annotate the total
repertoire data indicated that 5431 (0.85 %) of the total
repertoire clusters had similarity (same V and J and ≥96 %
CDR3 AA identity) to the HBsAg+ data obtained from this
study, 2832 (0.44 %) had similarity to the PC data from
this study, 833 (0.13 %) had similarity to the HBsAg+ data
from the booster study, and 505 (0.08 %) had similarity to
PC data from the booster study (Fig. 3a). The overlap in
the clusters annotated by each of these datasets was sig-
nificantly more than is expected by chance (Chi-square
test, p < 0.0001 for each overlap).
As some of the sequences in these vaccine-enriched
datasets may not actually be specific to the vaccine
antigen, due to either non-specific staining for HBsAg+
or the inclusion of some non-specific PCs, we used a
stricter definition of what we consider to be a vaccine-
specific cluster in our total repertoire dataset. To be
considered vaccine-specific, a cluster had to be anno-
tated as similar to at least two of these datasets, and
Vaccine 1 Vaccine 3Vaccine 2
Fig. 1 HBsAg-specific B-cell response kinetics determined by ELISpot and expressed as the number of antibody-secreting cells (ASC) per 106
peripheral blood mononuclear cells (PBMCs) used in each assay. PBMCs are used ex vivo to detect PCs and are cultured to detect memory cells.
Shown are the mean values ± standard error of the mean (SEM) for all nine participants. Detailed plots for each participant are shown in
Additional file 1: Figure S2
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also be present at a frequency greater than 0.01 % (i.e.,
contain at least eight sequences). On average, 0.8 % of
the frequent clusters were annotated as vaccine-specific
at visit 1, but this number increased to 1.2 % by visit 2
(Fig. 3b). The number increased further 7 days after
each of the two subsequent vaccines to peak at 1.5 % by
visit 6. The clusters annotated as vaccine-specific
tended to be large; when considering the percentage of
the repertoire comprised by these clusters, these post-
vaccination changes were thus more pronounced (Fig. 3c).
In total, 306 vaccine-enriched clusters (0.04 % of the
total clusters and 0.53 % of frequent clusters identified)
were found across all participants regardless of which
visit they were detected on. The percentage of frequent
clusters annotated as vaccine-specific in each participant
at each visit correlated with the number of HBsAg-
specific memory cells and PCs detected by ELISpot
(Fig. 3d, e), giving validity to the technique for enriching
vaccine-specific clusters.
The vaccine-specific repertoire has distinct features when
compared with the total repertoire
Next, we compared the properties of the vaccine-specific
clusters and the total repertoire. For comparison, a ran-
dom selection of 306 clusters that were not annotated as
vaccine-specific was obtained from the total repertoire.
As the size of the vaccine-specific clusters was much
greater than that of the random clusters (Fig. 4a), a size-
matched selection of random clusters was also obtained.
The vaccine-specific clusters had similar levels of muta-
tion to the random clusters but had significantly shorter
CDR3 lengths (Fig. 4b, c). The vaccine-specific clusters
were also more likely to be present both at multiple
timepoints and in multiple individuals compared with
Fig. 2 Fluctuations in the total repertoire. a Mean percentage of the total repertoire comprising the 50 most frequent clusters at each day
(see also Additional file 1: Figure S3). b Mean number of V gene mutations from all sequences in the repertoire. c Mean CDR3 AA sequence
length from all sequences in the repertoire. For a–c, error bars indicate ± SEM from nine participants. d The percentage of clusters shared by
each pair of participants at each visit was determined (nine participants, giving 36 pairings). Shown are the mean values ± SEM of the
percentage of clusters shared between each pair. Percent is calculated as (A∩B/size(A∪B)) × 100. Shared clusters are defined as those which
share the same V and J gene segment and cluster center CDR3 nucleotide sequence. All p values were obtained from Mann–Whitney
U tests
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the random clusters (Fig. 4d, e). It should be noted, how-
ever, that the vaccine-specific clusters are biased towards
commonality between individuals due to the way that
they were defined. The vaccine-specific clusters also had
a distinct profile of V gene segment usage, with a strik-
ing increase in usage of IGHV3–7 (Fig. 4f, g).
To investigate the structure of the clusters, lineage trees
were constructed from each of the vaccine-specific and
size-matched clusters that contained at least 50 total se-
quences (Fig. 4h). Structure of the lineage trees can give
insight into the relationships between clonal B cells within
the cluster and pathways of BCR evolution that have
Fig. 3 Enriching vaccine-specific clusters from the total repertoire. a The number of clusters from the total repertoire which were annotated by
the four vaccine-enriched sequence datasets. b The percentage of abundant (>0.01 % of total repertoire) clusters at each visit that were characterized
as vaccine-specific based on being annotated by at least two of the vaccine-enriched datasets. c Same as b but corrected for cluster size by consider-
ing the percentage of the repertoire comprising the vaccine-specific clusters. For b and c, mean values ± SEM are shown for all nine participants and p
values were obtained from two-sided Mann–Whitney U tests. d Correlation (Spearman) between the percentage of abundant clusters characterized as
vaccine-specific and PC numbers determined by ELISpot. Different colored points represent samples from the different participants. e Same as d but cor-
related with memory cell numbers determined by ELISpot. For d and e, samples where no cells were detected by ELISpot have been omitted
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occurred through proliferation and selection following
antigen stimulation. Furthermore, by estimating the most
recent common ancestor to the clone, it is possible to
determine how mutated this sequence is compared
with the germ line sequence (Fig. 4h; trunk length)
and thus infer the maturation level of the initiating B
cell for each clone [19]. Vaccine-specific lineages both
contained a greater diversity of sequences (Fig. 4i)
and had a shorter trunk length (Fig. 4j) than the size-
matched random lineages, consistent with greater
proliferation during the study period and more recent
origin from germline.
Dynamics of the vaccine-specific repertoire and evidence
for IgG B cells at baseline participating in the response
Having identified a vaccine-specific repertoire with dis-
tinctive features, we next investigated the kinetics of
these clusters in each participant over the course of the
study (Fig. 5). There were considerable expansions of
vaccine-specific clusters 7 days after each vaccine in the
majority of cases and, within an individual, many of the
same clusters were recurrently expanded after each vac-
cine dose. While the number of these expanded clusters
was moderately correlated with the number of HBsAg-
specific PCs detected by ELISpot in each participant
Fig. 4 Comparing vaccine-specific clusters to a size-matched random set of clusters and a non-size-matched random set of clusters. a–c Differences in
size, number of V gene mutations, and CDR3 AA sequence length of the clusters belonging to the three datasets. Shown are the mean values ± SEM
of the 312 clusters in each dataset. Comparisons were performed using a t-test. d The number of visits where at least a single sequence from each
cluster was found was determined and the number of clusters present at different numbers of visits in the different datasets plotted. e Same as d but
counting the number of participants where a similar cluster was found (same CDR3 cluster center sequence and V/J gene usage). f The proportion of
total clusters in the three different datasets utilizing different V gene segments in each participant. Error bars show mean values ± SEM of the nine par-
ticipants. g Principal component analysis of V gene segment usage of the clusters in each of the datasets. h Representative lineage trees of a vaccine-
specific and size-matched cluster. Each node represents a unique sequence within the cluster, with the size indicative of the number of duplicate se-
quences. The number within the node indicates the visit at which the sequence is first present. Shading of the node represents whether the sequence is
found in the cluster, an inferred common ancestor to sequences found in the cluster, or the germline sequence. Numbers on the edges of adjoining
nodes show the number of mutations between the sequences. i, j Lineage trees were created for all clusters which contained at least 50 sequences in
the dataset (N = 200). Diversity was calculated for each cluster using the Shannon index and trunk length is the number of mutations between the
most recent common ancestor and germline sequence. Shown are the mean values ± SEM. Comparisons were performed using a t-test
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(Fig. 3d), there were also striking expansions of the
vaccine-specific clusters 7 days after the first vaccine
despite no PCs being detected by ELISpot at this time.
Furthermore, many of the clusters expanding after each
vaccine were also present at low frequency at baseline
despite none of the participants having previously
encountered the vaccine antigen. The percentage of
vaccine-specific clusters after each vaccine, which were
also present at baseline, was similar after each vaccine
dose (Fig. 6a). Correlating the percentage of frequent
clusters annotated as vaccine-specific with the ELISpot
data revealed a strong correlation when considering only
the vaccine-specific clusters not present at baseline but
no correlation when considering the vaccine-specific
Fig. 5 Kinetics of the vaccine-enriched clusters. The vaccine-enriched clusters were found in each participant and, at each day, the frequencies of
these clusters are plotted as a stacked bar chart, centered to the middle of the y-axis. Clusters from each day are then joined using a horizontal
stream to illustrate how the frequency of the clusters changes over time. The width of the stream represents the frequency of the cluster at that
time and the color of the stream represents the first visit at which sequences from the cluster can be found. The top four plots are from participants
who were given the accelerated vaccine schedule and the bottom five plots are from participants who were given the conventional vaccine schedule.
Dotted vertical lines highlight the day 7 post-vaccination visits. *The day 168 blood sample was missing from this participant but the vaccine was still
given on this day. See also Additional file 1: Figure S4 and Table S3 for kinetics of vaccine-enriched clusters as defined by similarity to previously publish
HBsAg-specific monoclonal antibody sequences
Fig. 6 Vaccine-enriched clusters present at baseline. a In each of the nine participants, of the vaccine-specific clusters present at each
post-vaccination time point (visit 2, 4, or 6), the percentage of these that were also present at baseline was determined. Mean ± SEM
shown. b Correlation (Spearman) between the percentage of abundant clusters characterized as vaccine-specific and PC numbers determined
by ELISpot, split according to whether the vaccine-specific clusters are also present at baseline. Different colored points represent samples from the
different participants
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clusters that are present at baseline (Fig. 6b), suggesting
that the baseline clusters are inherently different to
those first identified at later visits and by ex vivo
ELISpot.
One potential reason for finding these vaccine-specific
clusters at baseline is due to insufficient stringency in
our definition of what comprises a vaccine-specific clus-
ter and that they are not actually specific to the vaccine.
To investigate the presence at baseline of BCR se-
quences with specificity for the vaccine antigen, we col-
lated a database of characterized HBsAg-specific
antibodies from the literature. In total, 12 previously de-
scribed sequences [20–23] mapped to clusters in our
dataset based on CDR3 AA sequence identity, allowing
one AA mismatch per 12 AAs (Additional file 1: Table
S3). Although there were not enough of these clusters
present to construct detailed plots of their kinetics, we
did also observe that seven of these were found at base-
line across six of the participants (Additional file 1: Fig-
ure S4).
We hypothesized that the clusters annotated as
vaccine-specific that are also present at baseline were de-
rived from memory B cells stimulated previously by a
different antigen but that are also able to recognize
HBsAg. These memory B cells might be expected to
have a relatively low affinity for HBsAg, such that ELI-
Spot had insufficient sensitivity to detect them. Higher
affinity B cells detectable by ELISpot are then formed
from activation of naïve B cells following the second and
third vaccines.
Distinct features of the vaccine-specific clusters after each
vaccine dose
To investigate the hypothesis that the response to the
first vaccine dose resembles cross-reactive memory re-
call compared with a naïve response after the second
two vaccine doses, the properties of the vaccine-specific
clusters that were found 7 days after each of the three
vaccinations were investigated in more detail. At each
visit there are two populations of clusters—those newly
generated in response to the vaccine and those that were
also present at an earlier visit and are being re-
stimulated—so the clusters were split by the visit at
which they were first detected in order to reflect this.
Considering the mutation level of the clusters, those first
found after the second and third vaccine doses were sig-
nificantly less mutated than those found after the first
vaccine dose (Fig. 7a). Those found after the first vaccine
dose and also after the later vaccine doses retained a
similar level of mutation throughout. Where these clusters
contained at least 25 sequences, lineage trees could be
constructed from them. The trunk length of the lineages
followed a similar pattern to mutation of the clusters.
Lineages of clusters first found after the second and third
doses had significantly shorter trunk lengths than those
found after the first vaccine dose, indicating that the clus-
ters found after the first vaccine dose were derived from
more mature precursor cells than those first found after
the second and third doses (Fig. 7b). Considering the di-
versity of sequences within the lineages, this was greater
for clusters first found after the second and third vaccine
doses compared with those found after the first vaccine
dose (Fig. 7c). Furthermore, for the clusters that are
present after the first vaccine dose, these became more di-
verse after the subsequent doses. Analyzing the selection
strength of the clusters revealed that the positive selection
strength was lower for the clusters found after the first
vaccine dose compared with those first appearing after the
subsequent vaccine doses (Fig. 7d). So, while the absolute
number of mutations is lower in the clusters found after
the second and third vaccine doses compared with the
first vaccine dose, these mutations are strongly selected
for and more likely to result in an amino acid difference.
Taken together, the data presented in Fig. 7 provide
evidence that the response to the first vaccine dose is
dominated by activation of pre-mutated memory B cells,
while less mutated naïve cells are also used in the re-
sponse to the subsequent doses. It also appears that
these pre-mutated memory B cells undergo more diver-
sification than the naïve cells. At visit 6, the timing of
the vaccine dose was different in the two vaccine groups,
which may have impacted the properties of the lineages,
but the study was not powered to detect such effects. It
is interesting to note that although not significant, the
average trunk length and number of mutations of the
lineages is reduced after the third dose in the 0, 1, 2
group compared with the 0, 1, 7 group (Additional file 1:
Figure S5).
Discussion
We used high-throughput sequencing of the human BCR
heavy chain repertoire to gain insight into B-cell dynamics
following repeated vaccination with an antigen to which
the participants had no prior exposure (HBsAg). We show
that vaccine-induced changes in the total repertoire fol-
lowing vaccination involve a small minority of sequences,
making them challenging to distinguish from background
fluctuations. By focusing on the vaccine antigen-specific
repertoire, we were able to gain clearer and more detailed
insight into the vaccine-induced B-cell dynamics than has
previously been possible. We were thus able to demon-
strate that a large proportion of the responding sequence
clusters are present at baseline in an IgG population
(~50 %) and have features which suggest that they are a
mature population previously generated in response to a
presumably unrelated antigen. The involvement of these
clusters in response to HepB vaccine suggests that they
also have a degree of cross-reactivity with HBsAg.
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We have previously demonstrated that, in the context
of a HepB booster vaccine, the features of the global B-
cell repertoire change (increase in cluster expansion, in-
crease in mutation, increase in repertoire convergence
between participants, and decrease in CDR3 length) [2].
These changes also occur in the current dataset and, as
before, are somewhat obscured by background fluctua-
tions in the non-specific repertoire of these individuals
that obscure the vaccine-specific effects [10]. Additional
noise may also come from the use of two different vac-
cination schedules. Furthermore, strong hallmarks of
repertoire activation were observed in at least two of the
participants in this study prior to any vaccination,
highlighting the need to focus on the vaccine-specific
repertoire rather than the total repertoire. To this extent,
we used cell sorting to isolate and sequence vaccine-spe-
cific cells and used a strict procedure to identify the
vaccine-specific clusters within the total repertoire. We
note, however, that despite referring to these clusters as
“vaccine-specific”, we cannot be certain of their specificity
as we are unable to express and characterize them due to
lack of having a paired light chain. This is a limitation that
should be removed in future studies as techniques for
high-throughput pairing of heavy and light chains emerge
[24]. Comparison of our vaccine-specific clusters to ran-
dom size-matched clusters does, however, reinforce our
idea that they are specific to the vaccine as they tend to be
more recently activated from germline and undergo in-
creased diversification during the course of the study. It is
worth noting that it is necessary to bear in mind some
limitations when interpreting lineage tree data. First, se-
quencing and PCR errors introduce some erroneous
sequences, which may be evident in the lineages as large
canopies of small closely related nodes (erroneous) arising
from the larger central nodes (correct). Such error is
evident in the example size-matched lineage (Fig. 4h) and
reduces the accuracy at which lineage diversity can be cal-
culated. While methods do exist to try and remove erro-
neous sequences [25], we did not use them here due to
concern that real sequences arising from somatic hyper-
mutation could also be removed (perhaps in a biased
manner), thus reducing our sensitivity of detecting true
Fig. 7 Properties of vaccine-enriched clusters present at each of the three day 7 post-vaccination visits. At each visit, the clusters were split according
to the visit when they were first identified. a Difference in number of V gene mutations of vaccine-enriched clusters at each visit. b, c Lineage trees
were constructed where these clusters contained at least 25 sequences and the trunk length (b) and sequence diversity within the lineage
(c) calculated for each. Mean values ± SEM are shown and the number of clusters is indicated at the bottom of each bar. Comparisons were
performed using a Mann–Whitney U test. See also Additional file 1: Figure S5. d Difference in selection strength in the CDR and framework
regions (FWR) of the clusters identified at different visits. Mean values ± 95 % confidence interval are shown
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diversification. Instead, we prefer to be cognizant of the
error and take this into account during interpretation of
the data. Any error should systematically affect all lineages
in the same way and so should not affect the conclusions
presented here. In fact, if the large canopies of the size-
matched lineages are truly erroneous, it would further de-
crease their diversity in relation to the vaccine-enriched
lineages. For future work, molecular barcoding could be
used to reduce the impact of such error [26]. Furthermore,
it is currently not possible to conduct lineage assignment
with complete confidence, so some lineages may con-
tain distinct erroneous nodes which may be members
of different lineages [27]. For example, the node in the
vaccine-enriched lineage, which is 26 mutations away
from the most recent common ancestor of the lineage,
could represent such an erroneous node. These errone-
ous nodes will have little influence on the trunk length
measurements but will equally impact all lineages, thus
not affecting our broad conclusions (Fig. 4h).
Studying the vaccine-specific repertoire yielded a
number of interesting observations. It is striking that
prior to vaccination all participants had clusters anno-
tated as vaccine-specific despite never having previously
encountered the vaccine antigen. Whilst this may be
expected in the naïve repertoire, we sequenced only the
class-switched IgG repertoire. This population represents
previously activated cells so is not expected to contain
cells specific to the antigen. Although finding vaccine-
specific sequences at baseline could represent an artifact
from incorrect labeling of the vaccine-specific repertoire,
we also find sequences matching previously characterized
HBsAg-specific antibodies from the literature at baseline,
indicating that this is not the case. It seems likely, there-
fore, that the clusters present at baseline represent B cells
that have previously been activated in response to differ-
ent antigens and that are either polyreactive or happen to
have a degree of cross-reactivity with HBsAg. Such a find-
ing is backed up by previous reports which show that
polyreactive B cells are a major constituent of the normal
human B-cell repertoire [28] and that these may be acti-
vated by specific antigens but then require a period of
maturation before they develop sufficient specificity to be
detected by methods such as ELISpot [29, 30]. Di Niro et
al. [29] generated monoclonal antibodies from PCs pro-
duced in response to Salmonella Typhimurium infection
and found that only a tiny fraction produced Salmonella-
specific antibodies and many appeared to be polyreactive
(measured using ELISA and protein microarray). By sub-
sequently characterizing the lineages of the Salmonella-
specific clones, they showed that initial selection was pro-
miscuous, activating both memory and naïve cells with
undetectable affinity for Salmonella, and Salmonella-spe-
cific cells within the lineages could only be detected once
there had been a greater degree of affinity maturation.
Williams et al. [30] generated monoclonal antibodies from
gp41-reactive B cells produced following HIV-1 envelope
protein vaccination, finding that many were non-
neutralizing and had some polyreactivity, possibly
explaining the vaccine failure. Further investigation also
revealed ancestors to the gp41-reactive cells were also
present prior to vaccination in one individual and were
being stimulated in a cross-reactive manner by the vac-
cine. These results back up our observations that cross-
reactive B cells to a novel antigen can be detected in
the memory compartment prior to antigen exposure
and it will be interesting to uncover the degree to
which such a phenomenon actually represents the nor-
mal response to any antigen.
Tracking the dynamics of the vaccine-specific reper-
toire revealed a degree of response after each of the
three vaccine doses. After the first vaccine dose, for
most participants, the majority of the responding clus-
ters were those that were also present at baseline,
highlighting the large extent to which recruitment of
these potentially cross-reactive B cells occurs. After
subsequent vaccines, there was more recruitment of
clusters that are not present at baseline, but some base-
line clusters were still recruited. This is indicative,
therefore, of recruitment of naïve vaccine-specific cells
occurring concomitantly to re-stimulation of the initial
cross-reactive cells. It is notable that despite detecting
these responses in the sequence data after the first vac-
cine, no responses were detected by ELISpot. It could
be that repertoire sequencing is simply a more sensitive
method for detecting the vaccine-specific effects (500,000
B cells used for repertoire sequencing versus 200,000
PBMCs per well for ELISpot) or, alternatively, that, be-
cause we suspect most of the B cells activated after the
first vaccine were derived from a cross-reactive response,
they are likely to have too low affinity for HBsAg for their
antibody to be detected by ELISpot. Indeed, this observa-
tion is backed up by our findings that, when selectively
considering the vaccine-specific clusters present at baseline,
their numbers do not correlate with the ELISpot data but,
when selectively considering the vaccine-specific clusters
not present at baseline, their numbers strongly correlate
with the ELISpot data. Plasmablasts that have only recently
differentiated and may not yet be secreting large amounts
of antibody could also preclude detection by ELISpot [31].
Conclusions
The data presented here provide insight into B-cell
dynamics following repeated antigen stimulus. We show
that focusing on the vaccine-specific repertoire is essen-
tial to reduce the background noise and that these data
yield additional insights beyond those available from
conventional techniques such as ELISpot. We uncover a
significant role of cross-reactive B cells in the response to
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HepB vaccine. It will be interesting to investigate whether
this also occurs in the response to other vaccines and the
degree to which cross-reactive activation affects the level
of protection conferred by the vaccine.
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